KRAS and non-small cell lung carcinoma: We first treated the KRAS-mutant human NSCLC cell lines (A549, KRASG12S; H460, KRASQ61H; SK-LU-1, KRASG12D; SW900, KRASG12V; H23, KRASG12C; H358, KRASG12C; SW1573, KRASG12C; and Calu-1, KRASG12C) with trametinib for 3 days.